Diego Ardigo | R&D Rare Diseases Unit Head
Chiesi Farmaceutici SpA

Diego Ardigo, R&D Rare Diseases Unit Head, Chiesi Farmaceutici SpA

Dr. Ardigò received his degree in Medicine and the specialization in Internal Medicine at the University of Parma (Italy). After a post-doctoral fellowship at Stanford University (California, US) he obtained a PhD degree in Cardiovascular Pathophysiology at the University of Parma. He is author of more than 40 indexed papers. He joined Chiesi in 2010 where acted as Clinical Lead in the development and registration of the first stem cell therapy in the EU (Holoclar®) and has been leading the cross-company team that led to the treatment of the first patient with a commercial gene therapy in EU (in alliance with uniQure BV). He is chairman of the Therapies Scientific Committee of IRDiRC (International Rare Diseases Research Consortium) and a member of the EBE-EFPIA ATMP Working Group.


Advanced Therapies and Regenerative Medicine Day 2 - Thursday 17th May 2018 @ 11:40

Panel discussion: Assessment of health technology and market access globally, challenges and pricing

  • How are the logistical challenges for cell and gene therapies going to work in the years ahead?
  • Affordability and sustainability. How are health authorities going to pay?
  • Process of health technology assessment
  • ROI considerations: what makes this product profitable?

back to speakers



Erica Baeta
+44 (0)207 092 1152


Jessica Robinson
t/ +44 (0)207 092 1150


Issa Mauthoor
+44 (0)207 092 1257